Press Releases

All Releases
View Summary Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10
Friday, February 26, 2016
PDF 6.6 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thursday, February 4, 2016
PDF 7.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Key Executive Appointments
Monday, February 1, 2016
PDF 11.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Preliminary Data From the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium
Thursday, January 21, 2016
PDF 15.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis (PVNS)
Wednesday, January 13, 2016
PDF 8.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Provides Update on FP-1039 Clinical Program
Monday, January 11, 2016
PDF 12.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Wednesday, January 6, 2016
PDF 9.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Prominent Immuno-Oncology Thought Leaders to Scientific Advisory Board
Tuesday, January 5, 2016
PDF 13.3 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Drug Development Leaders to Board of Directors
Thursday, December 3, 2015
PDF 14.8 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference
Tuesday, December 1, 2015
PDF 11.4 KB Add to Briefcase
View Summary Five Prime Therapeutics Begins Dose Expansion in Gastric Cancer Patients With FGFR2b Over-Expression in Phase 1 Trial of FPA144
Thursday, November 19, 2015
PDF 14.7 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Jefferies Autumn 2015 Global Healthcare Conference
Thursday, November 12, 2015
PDF 11.4 KB Add to Briefcase
View Summary Five Prime Therapeutics Receives Early HSR Clearance for FPA008 License and Collaboration Agreement With Bristol-Myers Squibb
Wednesday, November 11, 2015
PDF 12.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Preliminary FPA008 Phase 1 Data in Rheumatoid Arthritis Patients Presented at the 2015 ACR Annual Meeting
Tuesday, November 10, 2015
PDF 15.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Immuno-Oncology Research Activities Featured in Poster Presentations at SITC 2015
Thursday, November 5, 2015
PDF 15.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Reports Third Quarter 2015 Results and Provides Business Update
Wednesday, November 4, 2015
PDF 26.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 4
Wednesday, October 28, 2015
PDF 6.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
Thursday, October 15, 2015
PDF 12.9 KB Add to Briefcase
View Summary Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
Thursday, October 15, 2015
PDF 86.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces The Presentation of Preliminary FPA008 Phase 1 Trial Data in Rheumatoid Arthritis Patients at the 2015 ACR Annual Meeting
Wednesday, October 7, 2015
PDF 16.0 KB Add to Briefcase
Showing 41-60 of 160 Page: 1 2 3 4 5 6 7 8  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
36.84
Change (%)
0.00
Volume
N/A

Data as of 4:00 PM ET on Wednesday, March 29, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.